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Abstract
Insulin is a potent stimulator of intermediary metabolism, however the basis for the remarkable specificity of insulin’s
stimulation of these pathways remains largely unknown. This review focuses on the role compartmentalization plays in insulin
action, both in signal initiation and in signal reception. Two examples are discussed: (1) a novel signalling pathway leading to
the phosphorylation of the caveolar coat protein caveolin, and (2) a recently identified scaffolding protein, PTG, involved
directly in the regulation of enzymes controlling glycogen metabolism. (Mol Cell Biochem 182: 65–71, 1998)
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Introduction
Insulin is the most potent physiological anabolic agent known,
promoting the synthesis and storage of carbohydrates, lipids,
and proteins, and preventing their degradation and release back
into the circulation. Despite years of intense investigation,
there remains considerable uncertainty regarding the precise
intracellular events that mediate the actions of this hormone.
One confounding factor has been the variety of actions of
insulin, which depend upon cell type, time of exposure, and
the presence of other hormones [1]. Another is the fact that
insulin can act as a growth factor for cells in culture, and
shares many of the mitogenic signalling pathways elicited
by other growth factors. However, the metabolic effects of
insulin are unique, and cannot be reproduced with other
cellular stimuli [2–5]. Taken together, these findings indicate
that signalling mechanisms exist that respond uniquely to
insulin, which allow for the specialized effects of insulin on
metabolism.
Like receptors for many growth factors, the insulin
receptor is a tyrosine kinase that undergoes activation upon
insulin binding, leading to the tyrosine phosphorylation of
a specific collection of intracellular proteins [6, 7].
Receptor activation leads to a variety of signalling pathways
that diverge at or near the insulin receptor itself. While
receptor autophosphorylation and the subsequent substrate
phosphorylations are clearly required for the full expression
of insulin’s actions, many of these substrates and subsequent
downstream pathways are shared by other receptors that do
not mimic insulin’s effects on metabolism. A number of
hypotheses have been proposed to account for the signalling
specificity underlying insulin action, including differences
in the strength or duration of signals, combinatorial diversity
of signals, or other unique features of these pathways in
insulin responsive cells. Another potential mechanism to
explain insulin’s unique actions may lie in the spatial
compartmentalization of signal transduction [8, 9], both
regarding signal initiation at the plasma membrane, as well
as signal reception inside the cell. In this review we provide
two examples of how the subcellular targeting of signalling
molecules may contribute a key ingredient in determining
the specificity of insulin action.
Specificity in signal initiation: the role of caveolae
One clue to understanding how insulin can elicit its unique
actions may lie in the compartmentalization of the signalling
molecules themselves. Recent studies have suggested that
signal initiation may he functionally segregated into distinct
domains of the plasma membrane. Caveolae may represent
one type of specialized region of the plasma membrane that
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is crucial for specificity in signal transduction. Caveolae are
small invaginations of the plasma membrane with unique
protein and lipid compositions [10–13]. These structures are
clearly distinguished from clathrin-coated pits by their
characteristic striated coat, which is made up largely of the
caveolins [14, 15]. Caveolins are members of a multigene
family with three known members [16–20]. In many cell
types, caveolin copurifies with or binds to signalling
molecules [21–35], suggesting that one potential function
of caveolae lies in signal transduction.
Although caveolae have generated much recent interest,
their exact function and protein composition remain
controversial [36–39]. Other membrane domains with
biophysical properties similar to caveolae, such as clathrin
coated pits, can be contaminants in purified caveolar fractions
[40, 41], so that the precise molecular composition of these
structures is uncertain. Moreover, cellular membranes
contain sub-domains termed lipid ordered domains or
glycolipid rafts [42, 43]. These sub-domains, characterized by
their Triton-insolubility, are highly enriched in cholesterol,
glycolipids and sphingolipids, and de-enriched in phospho-
lipids. Many proteins are localized to the lipid ordered
domains by virtue of post-translational modifications. GPI
anchors have been shown to be necessary and sufficient for
the localization of proteins to these domains, as has tandem
acylation of the Src-family kinases and G-proteins [44–47].
Caveolin itself is also acylated [48]. Although the extent of
overlap between caveolae and glycolipid rafts is unknown,
it is clear that caveolae form within these lipid ordered
domains, perhaps due to the fact that caveolin is a cholesterol
binding protein [49]. While glycolipid rafts form in the
absence of caveolin [50, 51], expression of caveolins is both
necessary and sufficient to induce the formation of caveolae
[52–54]. Independently of whether all of the proteins which
co-purify with caveolins are actually found within the
caveolar structures, the membrane-bound proteins in the
lipid ordered domains are found in close proximity to the
caveolae, which form within these domains [38].
Caveolae are abundant in adipocytes and muscle, covering
a significant fraction of the inner surface of the plasma
membrane of adipocytes [55]. Of the four known forms of
caveolin, caveolins-1 (α and β) and -2 are most highly
expressed in adipocytes, followed by lung and muscle [17,
19, 56], while caveolin-3 appears to be a muscle specific
isoform [20, 57]. In addition, caveolin-1 expression increases
upon adipocyte differentiation [56, 59]. The abundance of
caveolae and caveolins in adipocytes and muscle, together
with their potential role in signalling, suggested a possible
role in insulin signal transduction. Consistent with an
important role for caveolae in insulin action, insulin
specifically stimulates the tyrosine phosphorylation of the
two forms of caveolin (22 and 24 kD) and an additional
unidentified protein of 29 kD that coimmunoprecipitates
with caveolin after disruption of the caveolar complexes with
octylglucoside [37]. This phosphorylation does not occur in
response to other growth factors in adipocytes. In addition,
caveolin phosphorylation occurs only in cells in which
metabolism is highly responsive to insulin. For example, it
occurs only in the fully differentiated 3T3-L1 adipocytes,
not in the preadipocytes, despite the expression of both
caveolin and the insulin receptor in both cell types [59].
Although insulin specifically increases the tyrosine
phosphorylation of caveolin, several lines of evidence
indicate that caveolin is not a direct substrate of the insulin
receptor. Analysis of caveolin-enriched fractions from
3T3-L1 adipocytes revealed that the caveolin kinase is the
Src-family kinase Fyn [37, 59]. Fyn colocalizes with
caveolin in low density, Triton-insoluble complexes in both
preadipocytes and adipocytes, and it is the only detectable
tyrosine kinase in these fractions. Moreover, overexpression
of wild type Fyn leads to an increase in the basal level of tyrosine
phosphorylation of caveolin, and hyperphosphorylation of
caveolin in response to insulin [59]. A dominant negative Fyn
construct blocked caveolin phosphorylation, although this
might reflect an indirect effect on differentiation. Interestingly,
the caveolin kinase in primary adipocytes appears to be the
Src-family kinase Lyn, rather than Fyn. Lyn is expressed at high
levels in primary adipocytes, and is colocalized with caveolin
in low density, Triton-insoluble complexes prepared from these
cells (unpublished observations).
How is the caveolar Fyn activated in response to insulin?
Fyn and other Src-family kinases can be regulated either
through the dephosphorylation of a regulatory tyrosine in
the carboxy terminus of the protein [60], or through the
occupancy of their SH2 domains by tyrosine phosphorylated
proteins [61]. The autophosphorylation of an additional
tyrosine is required for full activation of these kinases. No
net change in the phosphorylation of Fyn has been observed
in response to insulin in adipocytes, although there is a
significant increase in constitutive phosphorylation of Fyn
after adipocyte differentiation [59]. In addition, tyrosine
phosphorylated peptides which bind specifically to the SH2
domains of Fyn stimulate the caveolin kinase activity in
caveolar fractions, suggesting that the insulin receptor
phosphorylates a specific substrate protein, which in turn
activates the caveolar Fyn.
The unique conditions under which caveolin phosphoryl-
ation is observed suggest that the insulin receptor substrate
responsible for the activation of caveolar Fyn would have
several unique properties: (1) phosphorylation showing
specificity for insulin in adipocytes; (2) association with Fyn
(through an SH2 domain interaction) in response to tyrosine
phosphorylation; (3) translocation of the phosphorylated
protein into caveolae in response to insulin; and (4)
phosphorylation in 3T3-L1 adipocytes, but not in the
preadipocytes. While the well characterized insulin receptor
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substrates IRS-1/-2 and Shc emerged as potential candidates
[62, 63], none fulfilled all of these requirements. In contrast,
the proto-oncogene product c-Cbl shares many properties
with this presumed substrate protein. Insulin specifically
stimulates the phosphorylation of c-Cbl in adipocytes [64].
As has been observed in lymphocytes, Cbl constitutively
binds to Fyn in unstimulated adipocytes through an SH3
domain-mediated interaction, and insulin-stimulated
tyrosine phosphorylation of Cbl increases this association.
The Cbl which is phosphorylated in response to insulin
binds specifically to fusion proteins containing the SH2
domain of Fyn, but surprisingly not SHP-2 or PI3 kinase. Cbl
is translocated into caveolin-enriched Triton-insoluble
complexes after insulin stimulation, and the Cbl in these
complexes is tyrosine phosphorylated [59]. Most interest-
ingly, unlike the other known substrates of the insulin
receptor such as IRS-1/-2 and Shc, Cbl phosphorylation is
specific for the differentiated adipocyte phenotype. In
addition, tyrosine phosphorylation of Cbl is not observed in
tissue culture cell lines which have been engineered to
express high levels of the insulin receptor, while the other
substrate proteins are readily phosphorylated in these cells
[64].
The basis for the cell-type specificity of Cbl phos-
phorylation is currently unknown. Cbl is expressed at
comparable levels in both the preadipocytes and adipocytes.
Unlike IRS-1/-2 and Shc, Cbl does not contain a PTB domain,
which has been identified in substrates that interact directly
with the insulin receptor [65–67]. In addition, in contrast to
IRS-1 and Shc, Cbl does not interact with the insulin receptor
in the yeast two hybrid system. We hypothesize that tyrosine
phosphorylation of Cbl may require a specific adaptor
protein which allows for the interaction of Cbl with the insulin
receptor, and that it is the regulation of the expression of this
protein that accounts for the coordinate regulation of the
phosphorylations of Cbl and caveolin in response to insulin
in adipocytes. Although the model linking phosphorylation
of Cbl to the phosphorylation of caveolin through the activ-
ation of Fyn is compelling (Fig. 1), the exact relationship
between these three proteins is likely to be complex [68].
For example, Cbl may undergo processive phosphorylation
after the activation of Fyn [69, 70]. However, the insulin-
dependent association of Cbl and Fyn in caveolae leads to
the intriguing possibility that the Fyn/Cbl pathway may have
a unique function in adipocytes (phosphorylation of
caveolin) due to the localization of these proteins to
specialized domains of the plasma membrane.
The precise role of caveolin phosphorylation in insulin
action remains uncertain. Preliminary attempts to identify
proteins which interact with caveolin in a phosphorylation-
dependent manner have thus far proven unsuccessful.
However, the correlation between caveolin phosphorylation
and the metabolic activities of insulin [37, 59], the lack of
phosphorylation with other tyrosine kinase receptors [37,
59], and a number of reports describing numerous signalling
molecules in caveolae or related membrane domains [21–35]
suggest that this phosphorylation event may represent an
important mechanism for the segregation of early signalling
events in insulin action, perhaps as a way to ensure signalling
specificity.
Spatial compartmentalization in signal reception: the
regulation of glycogen metabolism
It has long been recognized that protein dephosphorylation
plays an essential role in regulating the metabolic effects
of insulin [71]. Indeed, many of the rate-limiting enzymes
involved in glycogen metabolism, such as glycogen synthase,
glycogen phosphorylase and phosphorylase kinase are
regulated by their phosphorylation state. Insulin causes the
dephosphorylation of these enzymes, which results in the
activation of glycogen synthase and the inactivation of
phosphorylase and phosphorylase kinase. This leads to a
significant increase in the rate of glycogen synthesis. The
dephosphorylation of these three enzymes is mediated
through the activation of the type I serine/threonine phosphatase
PP1 in response to insulin. However, insulin promotes the
net dephosphorylation of only a specific subset of proteins,
while PP1 and additional substrates for this enzyme are
found ubiquitously in nearly all cellular compartments.
Therefore, a mechanism must exist for the stimulation of
discrete PP1 activities by insulin.
The specificity with which insulin stimulates the de-
phosphorylation of only selected substrates of PP1 suggests
that there are distinct functional pools of PP1 in cells. Tissue
specific targeting subunits have been identified that localize
the catalytic subunit of PP1 (PP1C) to specific sites,
conferring both insulin sensitivity to the enzyme, as well as
substrate specificity. Several glycogen targeting proteins
have been described, including G
m
 which is expressed in
both heart and skeletal muscle [72], and G
L
, the hepatic
subunit [73]. While the precise functions of these proteins
remains uncertain, recent experiments on a related glycogen
localizing subunit of PP1C may help to explain how insulin
can promote the rapid dephosphorylation of the specific
group of proteins involved in glycogen metabolism. This
protein, called PTG for Protein Targeting to Glycogen, was
identified in a two-hybrid screen of a 3T3-L1 adipocyte
library using PP1C as the bait (74; also called R5, 75). PTG
encodes a 33 kD protein which is found in all insulin
responsive tissues. In addition to localizing PP1C to the
glycogen pellet, PTG forms specific complexes with the
PP1-regulated enzymes that control glycogen metabolism,
including glycogen synthase, phosphorylase, and phos-
phorylase kinase. PTG thus increases PP1 specific activity
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Fig. 1. Stimulation of the tyrosine phosphorylation of caveolin by insulin. Activation of the insulin receptor tyrosine kinase leads to the tyrosine
phosphorylation of Cbl. Phosphorylated Cbl binds to the SH2 phosphotyrosine binding domain of Fyn, which is resident in the caveolae. This activates the
kinase, resulting in the tyrosine phosphorylation of substrate proteins in these complexes such as caveolin.
against glycogen-bound substrates not only by targeting the
PP1 to glycogen, but also by directly interacting with PP1
substrate proteins. This protein, therefore, may assemble
glycogen synthase, phosphorylase, phosphorylase kinase, and
PP1C onto the glycogen particle, generating a metabolic
module for the localized reception of the appropriate
intracellular signals [74] (Fig. 2). It is still unclear, however,
whether all of the glycogen metabolizing enzymes are bound
to a single PTG molecule simultaneously, or if the binding
sites are shared between one or more proteins. It is expected
that the PP1 at this compartmentalized site is sensitive to
activation by insulin, while the non-responsive PP1 in other
subcellular compartments is not.
The mechanisms by which insulin specifically activates
glycogen-targeted PP1 are still unclear. At one time
speculation centered around the phosphorylation of two
closely spaced serine residues in the amino terminus of
G
m
, by the MAP kinase cascade [76 , 77]. However, it is
now clear that this model has shortcomings. MAP kinase-
activation is neither necessary nor sufficient for the
activation of glycogen synthase or PP1 by insulin [2–5, 78].
In addition, the phosphorylation sites in G
m
are not conserved
in the other glycogen targeting subunits [74]. While the
precise mechanisms involved in PP1 activation by insulin
remain uncertain, one attractive hypothesis involves
dis-inhibition of PP1 by the regulated dissociation of an
inhibitory subunit. Studies suggest that regulation of PP1
basal activity contributes to insulin responsiveness, and
that the low activity in the basal state is maintained by
phosphorylated inhibitory peptides such as inhibitor-1 and
DARPP-32 [79, 80]. For example, we have observed that
Fig. 2. PTG may act as a molecular scaffold for the hormonal control of
glycogen synthesis. The catalytic subunit of PP1 (PP1C) is targeted to
glycogen by PTG in 3T3-L1 adipocytes. PTG also serves as a glycogen
scaffolding protein, co-localizing PP1 with its substrate enzymes which control
glycogen metabolism, including glycogen synthase (GS), phosphorylase a
(Phos a), and phosphorylase kinase (Phos Kinase). This may serve as a
metabolic module for the localized reception of intracellular signals which
regulate glycogen metabolism.
adipocyte differentiation leads to a decrease in basal PP1
activity, and a significant increase in the stimulation of PP1
activity by insulin [81]. PP1 levels do not change during
ifferentiation, while expression of the PP1 inhibitor
peptide DARPP-32 is dramatically increased during adipo-
genesis [81], as is the PTG targeting subunit [82]. The
DARPP-32 in 3T3-L1 adipocytes is exclusively localized
to the particulate fraction [81], which includes the glycogen
pellet. We are currently testing the hypothesis that insulin
treatment leads to the dissociation of DARPP-32 from
glycogen targeted, PTG-bound PP1 (Fig. 3). In addition,
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Fig. 3. Activation of glycogen-targeted PP1 by insulin. Glycogen-targeted PP1 activity may be regulated by the binding of inhibitory peptides, such as
inhibitor 1 (inh-1) or DARPP-32. Insulin stimulation may cause the dephosphorylation and/or disassociation of bound inhibitor. Dis-inhibition of PP1 would
result in the dephosphorylation and activation of glycogen synthase, mediating the insulin-stimulated increase in glucose storage as glycogen.
attempts are underway to determine whether dissociation of
DARPP-32 is sufficient to account for the specific insulin-
induced dephosphorylation of enzymes involved in glycogen
metabolism. It is expected that lipid metabolism is similarly
regulated through additional, lipid-specific PP1 scaffolding
proteins.
Conclusions
We have focused much of our recent work on trying to
understand the mechanisms that account for the remarkable
specificity of insulin’s regulation of intermediary metabolism.
This specificity may be the result of the compartment-
alization of both signal initiation at the cell surface as well
as signal reception at the glycogen pellet or lipid droplet.
We have identified a novel, insulin-stimulated signalling
pathway which results in the tyrosine phosphorylation of
caveolin, a structural component of unique plasma mem-
brane domains termed caveolae. In addition, we have
identified a novel targeting protein, PTG, which forms a
distinct, insulin-sensitive pool of PP1 complexed with the
enzymes regulating glycogen metabolism. It is still unknown
whether these two pathways are linked. However, exploration
of the molecular details underlying the specificity of signal
initiation and signal reception in insulin action may elucidate
the complex biochemical pathways leading from the binding
of insulin at the cell surface to the regulation of intermediary
metabolism.
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